Anne-Marie Duliege Appointed to Governing Board of California's Stem Cell Agency

San Francisco, CA –Anne-Marie Duliege, MD, Chief Medical Officer of Affymax Inc., has been appointed to the Independent Citizens Oversight Committee (ICOC), the governing board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM).

“I am honored to have been appointed by the State Controller to this position” said Dr. Duliege. “I am delighted by this opportunity to join a talented group of experts and apply my knowledge in drug development at a time when several stem cell projects are approaching the step of clinical testing. I look forward to contributing to the advancement of one of most important avenues of future medical progress.”

Dr. Duliege has more than 20 years of leadership experience in the pharmaceutical industry, working at Chiron Corporation before Affymax and at Genetech prior to Chiron. In all her positions she has helped to steer therapies through multi-phase clinical trials.

She is filling one of the CIRM board positions reserved for someone from the life sciences industry that was previously filled by Ted Love. In making the appointment State Controller John Chiang said: “Dr. Duliege brings first-hand knowledge of what is required to take a drug from research phase through FDA approval.”

Dr. Duliege received her MD degree and her certificate in Pediatrics from Paris Medical School. She continues to practice medicine part time at Stanford School of Medicine and Lucile Packard Children’s Hospital.

“The state stem cell agency will benefit from having someone with Dr. Duliege’s experience on our board,” said Jon Thomas, JD, PhD, chair of the governing board. “Her experience in moving potential new therapies through the pre-clinical and clinical trials process will be invaluable as more of our awards fund work at this end of the research pipeline."

Profiles are available for all CIRM board members.

About CIRM: CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

© 2013 California Institute for Regenerative Medicine